Bevacizumab for refractory adverse radiation effects after stereotactic radiosurgery

Christopher P. Deibert; Manmeet S. Ahluwalia; Jason P. Sheehan; Michael J. Link; Toshinori Hasegawa; Shoji Yomo; Wu Han Feng; Pan Li; John C. Flickinger; L. Dade Lunsford; Douglas Kondziolka; Douglas Kondziolka

doi:10.1007/S11060-013-1214-3

Bevacizumab for refractory adverse radiation effects after stereotactic radiosurgery

Christopher P. Deibert
, Manmeet S. Ahluwalia
, Jason P. Sheehan
, Michael J. Link
, Toshinori Hasegawa
, Shoji Yomo
, Wu Han Feng
, Pan Li
, John C. Flickinger
, L. Dade Lunsford
, Douglas Kondziolka
, Douglas Kondziolka

Miami Cancer Institute

Research output: Contribution to journal › Article › peer-review

Original language	American English
Journal	Journal of neuro-oncology
Volume	115
DOIs	https://doi.org/10.1007/S11060-013-1214-3
State	Published - Aug 9 2013

Disciplines

Medicine and Health Sciences
Neurology
Radiology

Access to Document

10.1007/S11060-013-1214-3License: Unspecified

Cite this

@article{9c82c73b974642b7997ca9db657009c0,

title = "Bevacizumab for refractory adverse radiation effects after stereotactic radiosurgery",

author = "Deibert, \{Christopher P.\} and Ahluwalia, \{Manmeet S.\} and Sheehan, \{Jason P.\} and Link, \{Michael J.\} and Toshinori Hasegawa and Shoji Yomo and Feng, \{Wu Han\} and Pan Li and Flickinger, \{John C.\} and Lunsford, \{L. Dade\} and Douglas Kondziolka and Douglas Kondziolka",

note = "To retrospectively evaluate the clinical benefit and imaging response of bevacizumab when used to treat refractory adverse radiation effects (ARE) after stereotactic radiosurgery. Twenty-nine patients with brain tumors or vascular malformations developed clinical and/or imaging evidence of ARE after SRS and were treated using bevacizumab.",

year = "2013",

month = aug,

day = "9",

doi = "10.1007/S11060-013-1214-3",

language = "American English",

volume = "115",

journal = "Journal of neuro-oncology",

}

TY - JOUR

T1 - Bevacizumab for refractory adverse radiation effects after stereotactic radiosurgery

AU - Deibert, Christopher P.

AU - Ahluwalia, Manmeet S.

AU - Sheehan, Jason P.

AU - Link, Michael J.

AU - Hasegawa, Toshinori

AU - Yomo, Shoji

AU - Feng, Wu Han

AU - Li, Pan

AU - Flickinger, John C.

AU - Lunsford, L. Dade

AU - Kondziolka, Douglas

N1 - To retrospectively evaluate the clinical benefit and imaging response of bevacizumab when used to treat refractory adverse radiation effects (ARE) after stereotactic radiosurgery. Twenty-nine patients with brain tumors or vascular malformations developed clinical and/or imaging evidence of ARE after SRS and were treated using bevacizumab.

PY - 2013/8/9

Y1 - 2013/8/9

UR - http://europepmc.org/abstract/MED/23929592

U2 - 10.1007/S11060-013-1214-3

DO - 10.1007/S11060-013-1214-3

M3 - Article

VL - 115

JO - Journal of neuro-oncology

JF - Journal of neuro-oncology

ER -

Bevacizumab for refractory adverse radiation effects after stereotactic radiosurgery

Disciplines

Access to Document

Other files and links

Cite this